Gilead Sciences Current Valuation vs. Net Income
| GILD34 Stock | BRL 287.56 4.47 1.58% |
For Gilead Sciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Gilead Sciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Gilead Sciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Gilead Sciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Gilead Sciences over time as well as its relative position and ranking within its peers.
Gilead |
Gilead Sciences Net Income vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Gilead Sciences's current stock value. Our valuation model uses many indicators to compare Gilead Sciences value to that of its competitors to determine the firm's financial worth. Gilead Sciences is rated # 5 in current valuation category among its peers. It is rated # 4 in net income category among its peers making up about 0.01 of Net Income per Current Valuation. The ratio of Current Valuation to Net Income for Gilead Sciences is roughly 149.43 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Gilead Sciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Gilead Sciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Gilead Current Valuation vs. Competition
Gilead Sciences is rated # 5 in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers - Major industry is currently estimated at about 6.09 Trillion. Gilead Sciences retains roughly 686.18 Billion in current valuation claiming about 11% of equities under Drug Manufacturers - Major industry.
Gilead Net Income vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Gilead Sciences |
| = | 686.18 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Gilead Sciences |
| = | 4.59 B |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Gilead Net Income Comparison
Gilead Sciences is rated # 3 in net income category among its peers.
Gilead Sciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Gilead Sciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Gilead Sciences will eventually generate negative long term returns. The profitability progress is the general direction of Gilead Sciences' change in net profit over the period of time. It can combine multiple indicators of Gilead Sciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 11000 people.
Gilead Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Gilead Sciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Gilead Sciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Gilead Sciences' important profitability drivers and their relationship over time.
Use Gilead Sciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Gilead Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gilead Sciences will appreciate offsetting losses from the drop in the long position's value.Gilead Sciences Pair Trading
Gilead Sciences Pair Trading Analysis
The ability to find closely correlated positions to Gilead Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Gilead Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Gilead Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Gilead Sciences to buy it.
The correlation of Gilead Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Gilead Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Gilead Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Gilead Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Gilead Sciences position
In addition to having Gilead Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investing Thematic Idea Now
Investing
Companies involved in money management and investment banking services. The Investing theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Gilead Stock
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
To fully project Gilead Sciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Gilead Sciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Gilead Sciences' income statement, its balance sheet, and the statement of cash flows.